Advertisement
Advertisement
July 2, 2024
Pulnovo Commences Global Study of PADN Technology for Pulmonary Hypertension Associated With Left Heart Disease
July 2, 2024—Pulnovo Medical Limited announced the initiation of a global multicenter clinical study exploring the company’s percutaneous pulmonary artery denervation (PADN) treatment for pulmonary hypertension associated with left heart disease. The first two patients in the study were enrolled by Professor Ruben Ramos, MD, at Centro Hospitalar Universitário de Lisboa Central—Hospital de Santa Marta in Lisbon, Portugal.
Prof. Ramos and his team successfully performed the two PADN procedures under the guidance of Professor Hang Zhang, MD, from Nanjing Medical University Affiliated Nanjing Hospital in Nanjing, China.
“PADN technology shows great potential in treating pulmonary hypertension associated with left heart disease,” commented Prof. Ramos in Pulnovo’s press release. “We are delighted to be the first in Europe to participate in this global clinical study. Our team is confident in this project and looks forward to bringing more treatment options to European pulmonary hypertension patients through this study. PADN is not only a new treatment method but also brings new hope to patients suffering from pulmonary hypertension.”
Advertisement
Advertisement
